ESPR - NASDAQ

Esperion Therapeutics, Inc.

ESPR·NASDAQ

$3.14

+0.32%

HealthcareBiotechnology

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$652.83M

EPS-0.1100

P/E Ratio-28.55

Earnings Date08/04/2026

espr

Long Term Debt

Last Annual Value

457.65M

3-Year CAGR

21%

5-Year CAGR

21%

10-Year CAGR

67%

Adjust for Inflation

Esperion Therapeutics, Inc. Competitors Analysis of Long Term Debt

ESPR · NASDAQ

Company	Long Term Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Esperion Therapeutics, Inc. NASDAQ:ESPR	457.65M	-3.0%	12.1%	84.1%
SIGA Technologies, Inc. NASDAQ:SIGA	0.00	N/A	N/A	N/A
Emergent BioSolutions Inc. NYSE:EBS	572.10M	8.6%	-6.7%	8.7%
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS	0.00	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. NASDAQ:OLMA	69.00K	N/A	N/A	N/A
REGENXBIO Inc. NASDAQ:RGNX	147.41M	N/A	N/A	N/A
Ventyx Biosciences, Inc. NASDAQ:VTYX	0.00	N/A	N/A	N/A
Absci Corporation NASDAQ:ABSI	3.50M	-9.1%	25.5%	N/A
Orthofix Medical Inc. NASDAQ:OFIX	182.80M	25.2%	N/A	N/A
Aquestive Therapeutics, Inc. NASDAQ:AQST	115.48M	61.3%	17.5%	11.6%

Esperion Therapeutics, Inc. Fair Value Envelope

ESPR · NASDAQ

Our analysis suggests that ESPR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Esperion Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.14

Related Guides

Blog Categories

Continue your ESPR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.